U.S. Health Care REITs Stock News

Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are potentially priced below their intrinsic value can be a prudent strategy for investors seeking opportunities amidst fluctuating market conditions.

Over the last 7 days, the United States market has experienced a slight decline of 2.3%, although it has shown resilience with a 13% rise over the past year and an optimistic forecast of 16% annual earnings growth. In this dynamic environment, identifying stocks with strong potential often involves looking beyond well-known names to find those undiscovered gems that align with current growth trends and market conditions.

Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings forecasted to grow by 16% annually. In such a dynamic environment, selecting dividend stocks with reliable yields can provide stability and income potential for investors seeking to navigate market fluctuations.

Wondering whether Safety Insurance Group at around US$73.39 is a sensible entry or hold for you right now? This article focuses squarely on what the current price might imply about value. The stock has been fairly steady in the very short term with a 0.8% return over the last week. The past month shows a 6.4% decline and the year-to-date return sits at a 3.1% decline, alongside a 1.7% decline over the past year, a 14.6% return over three years and a 7.8% return over five years. Recent...

If you are wondering whether Helios Technologies at around US$67.54 is still attractively priced after a big run, the key question is what you are really paying for today. The stock has moved 4.0% over the last 7 days, sits on a year to date return of 23.5%, and has delivered 98.3% over the last year, although the past 30 days show a 9.0% decline that may have shifted perceptions of risk and opportunity. Recent coverage around Helios Technologies has focused on how its share price...

If you are wondering whether Ocugen's current share price still makes sense after a strong run, the key question is how that price lines up with the underlying value of the business. Ocugen shares, which last closed at US$1.92, have had a mixed but attention grabbing run, with a 21.6% decline over the last 7 days, a 20.0% gain over 30 days, 39.1% year to date, 168.6% over 1 year and 131.3% over 3 years, set against a 71.6% loss over 5 years. Recent news coverage has focused on Ocugen's...

Hesai Group (NasdaqGS:HSAI) has just posted its FY 2025 third quarter numbers, with revenue of C¥795.4 million and basic EPS of C¥1.88 setting the tone for the latest update. The company has seen quarterly revenue move from C¥458.9 million in Q2 2024 to C¥719.8 million in Q4 2024 and then to C¥795.4 million in Q3 2025. Basic EPS has shifted from a loss of C¥0.56 per share in Q2 2024 to C¥1.13 in Q4 2024 and C¥1.88 in Q3 2025, pointing to a business where margins are increasingly in focus for...

Last week's earnings announcement from Turtle Beach Corporation ( NASDAQ:TBCH ) was disappointing to investors, with a...

Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings forecasted to grow by 16% annually. In this context of fluctuating performance, identifying small-cap stocks with potential insider buying can be an intriguing strategy for investors seeking opportunities that may not be immediately apparent in larger market trends.

Over the last 7 days, the United States market has experienced a 2.3% drop, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking to capitalize on potential long-term gains amidst fluctuating market conditions.

Over the last 7 days, the United States market has experienced a 2.3% drop, yet it has shown resilience with a 13% rise over the past year and earnings are expected to grow by 16% annually. In such dynamic conditions, dividend stocks can offer investors stability and income potential, making them an attractive option for those seeking steady returns amidst market fluctuations.

Insiders who bought US$1.73m worth of Cartesian Therapeutics, Inc.'s ( NASDAQ:RNAC ) stock at an average buy price of...

We feel now is a pretty good time to analyse CollPlant Biotechnologies Ltd.'s ( NASDAQ:CLGN ) business as it appears...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

The US government has launched a multi trillion dollar consortium to support critical semiconductor and advanced manufacturing supply chains as part of an expanded Pax Silica program. The initiative aims to channel substantial funding into domestic fabrication, tooling, industrial lasers and related infrastructure over the medium term. IPG Photonics, listed as NasdaqGS:IPGP, sits within the industrial laser segment that is closely tied to these manufacturing and semiconductor build...

If you are wondering whether National Beverage at around US$33.71 is a bargain or a value trap, this breakdown will help you connect the share price to what the business may be worth. The stock is up 6.5% year to date, although it has seen a 2.6% slip over the last week and an 8.9% decline over the last month. The 1 year return of 16.1% and 3 year return of 31.2% highlight how sentiment has shifted over time. Recent coverage has focused on National Beverage's position in the soft drinks...

Veracyte, NasdaqGM:VCYT, has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer in a newly created executive role. Dr. Haas will oversee assay development, software, AI, and next generation informatics across Veracyte's product pipeline. The move reflects Veracyte's focus on whole genome MRD and multi omics applications across its global portfolio. Veracyte's share price stands at $32.94, with a return of 60.1% over the past 3 years and a 2.2% decline over the past...

Janus Living (NYSE:JAN) has arranged $600 million in new unsecured credit facilities. The package includes a $500 million unsecured revolving credit facility and a $100 million unsecured delayed draw term loan facility. The new funding is intended to increase liquidity and support future expansion plans. For investors watching NYSE:JAN, the new credit facilities arrive with the stock at $23.75 and a year-to-date return of 0.6%. The move reshapes Janus Living's funding options as a REIT and...

If you are wondering whether AvePoint's current share price lines up with its underlying worth, this breakdown will help you make sense of what the market is implying. The stock recently closed at US$9.61, with returns of 8.4% decline over 7 days, 8.5% decline over 30 days, 27.3% decline year to date, 36.9% decline over 1 year, 146.4% gain over 3 years, and 13.3% decline over 5 years, so the recent share price path has been mixed across different time frames. Recent news coverage has focused...

Recent Results Set the Stage for Battalion Oil’s Next Chapter Battalion Oil (BATL) just posted its latest FY 2025 numbers with Q3 revenue of US$43.5 million and a basic EPS loss of US$0.91, alongside trailing twelve month revenue of US$183.4 million and a basic EPS loss of US$3.35. Over the past few quarters, total revenue has moved between US$42.8 million and US$49.7 million while quarterly basic EPS has ranged from a loss of US$1.88 to a profit of US$0.34. This gives investors a mixed read...

Latest FY 2025 Results: Revenue Pressure and Deep Losses at Sutro Biopharma (STRO) Sutro Biopharma (STRO) has put out fresh FY 2025 numbers, with Q3 total revenue of US$9.7 million, a basic EPS loss of US$6.70, and net income loss excluding extra items of US$56.9 million setting the tone for the update. The company has seen quarterly revenue move between US$8.5 million and US$63.7 million over the last six reported periods, while basic EPS has ranged from a loss of US$1.36 to a loss of...

BioAge Labs (BIOA) just posted its FY 2025 third quarter numbers, reporting revenue of US$2.1 million and a basic EPS loss of US$0.56, alongside a net loss of US$20.2 million, keeping the story firmly in loss-making territory. Over recent quarters, revenue has moved from US$0 million in Q4 2024 to US$1.5 million in Q1 2025 and US$2.4 million in Q2 2025. Quarterly basic EPS has remained in loss-per-share territory between US$0.36 and US$0.60, which keeps the focus on the pace at which losses...

Wondering whether ArcBest at around US$94.60 is offering value right now or asking too much of future expectations? This article breaks down what the current price could be telling you. The share price has moved 10.1% over the last 7 days, while the 30 day return stands at a 10.0% decline and the 1 year return is 29.7%, with 22.6% year to date. Recent news coverage has focused on ArcBest as a transportation and logistics player in a sector that often reacts quickly to shifts in freight...